Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Su Jung Kang"'
Autor:
Dong-Jin Han, Sunmin Kim, Seo-Young Lee, Youngbeen Moon, Su Jung Kang, Jinseon Yoo, Hye Young Jeong, Hae Jin Cho, Jeong Yang Jeon, Byeong Chang Sim, Jaehoon Kim, Seungho Lee, Ruibin Xi, Tae-Min Kim
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-20 (2024)
Abstract Background Determining the impact of somatic mutations requires understanding the functional relationship of genes acquiring mutations; however, it is largely unknown how mutations in functionally related genes influence each other. Methods
Externí odkaz:
https://doaj.org/article/f2bc79ae35be430a9afb4d75ad0ce6bf
Autor:
Dong-Jin Han, Sunmin Kim, Seo-Young Lee, Su Jung Kang, Youngbeen Moon, Hoon Seok Kim, Myungshin Kim, Tae-Min Kim
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Background: Previous studies have reported that genes highly expressed in leukemic stem cells (LSC) may dictate the survival probability of patients and expression-based cellular deconvolution may be informative in forecasting prognosis. However, whe
Externí odkaz:
https://doaj.org/article/f9d97faac61a4e64804aa6176d94d2a4
Autor:
YoungJoon Park, JeongMan Park, Ju Won Ahn, Jeong Min Sim, Su Jung Kang, Suwan Kim, So Jung Hwang, Song-Hee Han, Kyoung Su Sung, Jaejoon Lim
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 2281-2295 (2021)
Glioma accounts for 80% of all malignant brain tumours and is the most common adult primary brain tumour. Age is an important factor affecting the development of cancer, as somatic mutations accumulate with age. Here, we aimed to analyse the signific
Externí odkaz:
https://doaj.org/article/a21b9deffe3943aea5ed077933579bd7
Autor:
Jaejoon Lim, YoungJoon Park, Ju Won Ahn, JeongMin Sim, Su Jung Kang, Sojung Hwang, Jin Chun, Hyejeong Choi, Sang Heum Kim, Duk-Hee Chun, Kyoung Su Sung, KyuBum Kwack, Kyunggi Cho
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0247293 (2021)
Glioblastoma multiforme (GBM) is an aggressive malignancy classified by the World Health Organization as a grade IV glioma. Despite the availability of aggressive standard therapies, most patients experience recurrence, for which there are currently
Externí odkaz:
https://doaj.org/article/fda1906ae3d647189148f840365d31a9
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 5, p 2900 (2022)
Neonatal hypoxic–ischemic encephalopathy (HIE) results in neurological impairments; cell-based therapy has been suggested as a therapeutic avenue. Previous research has demonstrated the synergistically potentiated therapeutic efficacy of human umbi
Externí odkaz:
https://doaj.org/article/59aecd48e5b548dc8f0b52ecdde36b0d
Autor:
JeongMan Park, Kyoung Su Sung, Song-Hee Han, Young-Joon Park, So Jung Hwang, Su Jung Kang, Ju Won Ahn, Jeong Min Sim, Suwan Kim, Jaejoon Lim
Publikováno v:
Current Oncology, Vol 28, Iss 210, Pp 2281-2295 (2021)
Current Oncology
Volume 28
Issue 3
Pages 210-2295
Current Oncology
Volume 28
Issue 3
Pages 210-2295
Glioma accounts for 80% of all malignant brain tumours and is the most common adult primary brain tumour. Age is an important factor affecting the development of cancer, as somatic mutations accumulate with age. Here, we aimed to analyse the signific
Autor:
Su-Jung Kang
Publikováno v:
Urimal Society. 62:93-137
Autor:
Su-Jung Kang
Publikováno v:
Teaching Korean as a Foreign Language. 54:1-46
Autor:
KyuBum Kwack, Ju Won Ahn, So Jung Hwang, Kyung Gi Cho, Young-Joon Park, Su Jung Kang, Jaejoon Lim
Publikováno v:
Cancers
Volume 12
Issue 9
Cancers, Vol 12, Iss 2543, p 2543 (2020)
Volume 12
Issue 9
Cancers, Vol 12, Iss 2543, p 2543 (2020)
Oligodendroglioma (OD) is a subtype of glioma occurring in the central nervous system. The 1p/19q codeletion is a prognostic marker of OD with an isocitrate dehydrogenase (IDH) mutation and is associated with a clinically favorable overall survival (
Autor:
Ju Won Ahn, Duk-Hee Chun, Sojung Hwang, Kyung Gi Cho, JeongMin Sim, Sang Heum Kim, Young-Joon Park, Kyoung Su Sung, Jaejoon Lim, Su Jung Kang, KyuBum Kwack, Jin Chun, Hyejeong Choi
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 3, p e0247293 (2021)
PLoS ONE, Vol 16, Iss 3, p e0247293 (2021)
Glioblastoma multiforme (GBM) is an aggressive malignancy classified by the World Health Organization as a grade IV glioma. Despite the availability of aggressive standard therapies, most patients experience recurrence, for which there are currently